| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T46 |
0-382 |
Sentence |
denotes |
Next, we expressed and purified several representative SARS-CoV-specific antibodies which have been reported to target RBD and possess potent neutralizing activities, including m396 [3], CR3014 [4], CR3022 [5], as well as a MERS-CoV-specific human monoclonal antibody m336 developed by our laboratory [15], and measured their binding ability to 2019-nCoV RBD by ELISA (Figure 1(e)). |
| T47 |
383-482 |
Sentence |
denotes |
Surprisingly, we found that most of these antibodies did not show evident binding to 2019-nCoV RBD. |
| T48 |
483-558 |
Sentence |
denotes |
To confirm this result, we further measured the binding kinetics using BLI. |
| T49 |
559-623 |
Sentence |
denotes |
An irrelevant anti-CD40 antibody was used as a negative control. |
| T50 |
624-785 |
Sentence |
denotes |
Similarly, the antibody m396, which was predicted to bind 2019-nCoV RBD (Figure 1(d)), only showed slight binding at the highest measured concentration (2.0 µM). |
| T51 |
786-935 |
Sentence |
denotes |
Further studies are needed to solve the high-resolution structure of 2019-nCoV RBD and understand why it could not be recognized by these antibodies. |
